Market Place
Sourcing Support
Bausch+Lomb: New Data On Consumer, Vision, Pharma Products At Optometry Meet
28 May 2024 //
BUSINESSWIRE
Bausch + Lomb Launches MIEBO in the United States
12 Sep 2023 //
BUSINESSWIRE
Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03
13 Jun 2023 //
BUSINESSWIRE
Bausch + Lomb and Novaliq win approval for dry eye disease treatment
19 May 2023 //
ENDPTS
Bausch + Lomb & Novaliq Announce Publication of Phase 3 Data on NOV03
22 Mar 2023 //
BUSINESSWIRE
Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03
04 Jan 2023 //
BUSINESSWIRE
Bausch + Lomb & Novaliq Announce USFDA Filing Acceptance for Investig. NOV03
06 Sep 2022 //
PRNEWSWIRE
Bausch + Lomb and Novaliq Submit NDA for Investigational Treatment NOV03
07 Jul 2022 //
PRNEWSWIRE
Bausch + Lomb Presents Data from Second Pivotal PIII Trial of NOV03
03 May 2022 //
BAUSCHHEALTH
Bausch + Lomb Presents Data from 1st Pivotal Ph 3 Trial of Investigational NOV03
25 Apr 2022 //
PRNEWSWIRE
PHASE 3 OF SHR8058 EYE DROPS SHOWS STATISTICALLY SIGNIFICANT TOPLINE RESULTS
15 Dec 2021 //
PRNEWSWIRE
Bausch + Lomb Completes Enrollment Of Second Phase 3 Study For NOV03
07 Jul 2021 //
PR NEWSWIRE
Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03
19 Jan 2021 //
PRNEWSWIRE
Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03
18 Jan 2021 //
PRNEWSWIRE
Novaliq Raises New Capital to Accelerate the Commercialization of its Lead Products for Dry Eye Disease
11 Oct 2018 //
BUSINESSWIRE
Novaliq’s NovaTears®+Omega-3 Approved in EU - Enhanced Treatment Dry Eye Disease
06 Dec 2017 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.